SHERIDAN, WYOMING - December 26, 2025 - The Yokohama Rubber Co., Ltd. is reshaping its senior leadership structure from January 1, 2026, sharpening its focus on tire production efficiency, advanced materials development, and growth in China and Asia across both tire and industrial product lines. The new appointments consolidate operational responsibility around key associates, signaling a push toward tighter coordination between manufacturing, R&D and regional business development.

Strengthening leadership around tire production and investment planning

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber is leveraging the global reach of the Gymkhana stunt-film franchise to spotlight its ADVAN flagship performance tires, with the latest episode "Gymkhana: Aussie Shred" showcasing ADVAN-equipped Subaru machinery and racking up more than 5.3 million views in its first week online.

ADVAN brand visibility in a high-impact global stunt platform

The new film, released on Hoonigan Media Machine's official YouTube channel on December 9, 2025, is the third consecutive Gymkhana installment to feature ADVAN tires as original equipment on the lead vehicle.
Co-produced by Hoonigan Media Machine, 321 Action Action and Subaru Motorsports USA, the series has become a global benchmark for extreme driving content, delivering sustained visibility for tire and performance brands among highly engaged enthusiasts.

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber is deepening its sustainability strategy and raw materials risk management by supporting an international joint research project in Indonesia aimed at preventing rubber tree leaf fall diseases, a growing threat to global natural rubber production and the tire industry's long-term resilience.

Securing Natural Rubber at the Source in Indonesia

The company is cooperating in the multi-year project "Development of Complex Technologies for Prevention and Control of Rubber Tree Leaf Fall Diseases," which targets one of the most serious plant health challenges facing natural rubber plantations in Indonesia, the world's second-largest producer.
Leaf fall disease has become widespread in key growing regions, leading to significant yield losses and jeopardizing supply for industrial users, including tire manufacturers.

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber has expanded its presence in the electric vehicle supply chain as Nissan chooses the AVID GT as original equipment for the new Nissan LEAF in the United States, underlining the growing role of EV-optimized tire technology in improving range, comfort and safety for mainstream electric cars.

EV-Optimized Tires for a Core Mass-Market Electric Vehicle

Yokohama Rubber has begun supplying its AVID GT in size 215/55R18 95H as factory equipment for the latest Nissan LEAF EV launched in the U.S. market in 2025. Positioned as a key electric model for drivers transitioning from internal combustion engines to battery-electric vehicles, the new LEAF benefits from a tire package specifically engineered to support higher curb weights, instant torque and demanding efficiency targets.

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber is strengthening its position in Japan's highly competitive mini-vehicle segment as it begins supplying its fuel-efficient BluEarth-FE AE30 tire as original equipment for Nissan's new Roox, launched in 2025 and equipped in selected grades with 155/65R14 75S fitments.

Fuel-efficient OE tire for Japan's next-generation kei car

The OE deal places Yokohama's BluEarth-FE AE30 at the heart of one of Japan's most important volume segments: compact, city-focused mini-vehicles. Built under the BluEarth brand concept of being "environmentally, human, and socially friendly," the BluEarth-FE AE30 is positioned as a standard tire that balances rolling resistance, safety and comfort - critical factors for OEMs seeking to meet fuel-efficiency regulations and customer expectations in urban use.

SHERIDAN, WYOMING - December 24, 2025 - UAE operator du has signed a three-year agreement with Huawei after deploying what the companies describe as the world's first 25Gbps E-band microwave link to support a 5G-Advanced (5G-A) site rollout, aiming to boost capacity and consistency where fiber backhaul is limited.

From "site upgrades" to backhaul strategy
5G-Advanced pushes more traffic through the radio layer, but the customer experience still hinges on the transport network behind it. du framed the partnership as a joint innovation framework-not just procurement-designed to keep pace with surging data transmission demand while accelerating scalable 5G-A coverage across the UAE, including areas where fiber deployment is slower or impractical.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.

SHERIDAN, WYOMING - December 19, 2025 - Voyager Therapeutics is laying off 30 employees after partner Novartis discontinued two undisclosed discovery-stage programs under the companies' gene therapy collaboration, underscoring how quickly platform-driven R&D bets can be reprioritized even inside marquee pharma partnerships.

Commercial partnerships can shift overnight
Voyager disclosed last month that Novartis had stepped away from two early programs tied to their ongoing relationship, without naming the assets or detailing the rationale. The biotech framed the change as manageable, stating that Novartis' decision will "not impact Voyager's cash runway guidance." Still, the workforce reduction signals that operational resets often follow partnership scope changes-especially when programs are preclinical and the near-term value is concentrated in a smaller set of advancing assets.

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.